JP2007533670A5 - - Google Patents

Download PDF

Info

Publication number
JP2007533670A5
JP2007533670A5 JP2007508701A JP2007508701A JP2007533670A5 JP 2007533670 A5 JP2007533670 A5 JP 2007533670A5 JP 2007508701 A JP2007508701 A JP 2007508701A JP 2007508701 A JP2007508701 A JP 2007508701A JP 2007533670 A5 JP2007533670 A5 JP 2007533670A5
Authority
JP
Japan
Prior art keywords
composition
cytarabine
daunorubicin
liposome
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007508701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533670A (ja
JP4972545B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2005/000625 external-priority patent/WO2005102359A1/en
Publication of JP2007533670A publication Critical patent/JP2007533670A/ja
Publication of JP2007533670A5 publication Critical patent/JP2007533670A5/ja
Application granted granted Critical
Publication of JP4972545B2 publication Critical patent/JP4972545B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007508701A 2004-04-22 2005-04-22 アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤 Expired - Lifetime JP4972545B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56521004P 2004-04-22 2004-04-22
US60/565,210 2004-04-22
PCT/CA2005/000625 WO2005102359A1 (en) 2004-04-22 2005-04-22 Liposomal formulations of anthracycline agents and cytidine analogs

Publications (3)

Publication Number Publication Date
JP2007533670A JP2007533670A (ja) 2007-11-22
JP2007533670A5 true JP2007533670A5 (enExample) 2011-04-21
JP4972545B2 JP4972545B2 (ja) 2012-07-11

Family

ID=35196733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007508701A Expired - Lifetime JP4972545B2 (ja) 2004-04-22 2005-04-22 アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤

Country Status (13)

Country Link
US (2) US8022279B2 (enExample)
EP (2) EP2407169A1 (enExample)
JP (1) JP4972545B2 (enExample)
AU (1) AU2005235455B2 (enExample)
BE (1) BE2018C045I2 (enExample)
CA (1) CA2564542C (enExample)
CY (2) CY1113012T1 (enExample)
ES (1) ES2388064T3 (enExample)
FR (1) FR18C1047I2 (enExample)
IL (1) IL178779A (enExample)
NL (1) NL300960I2 (enExample)
PT (1) PT1744764E (enExample)
WO (1) WO2005102359A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032136A1 (en) * 2004-09-20 2006-03-30 British Columbia Cancer Agency Branch Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US20100303895A1 (en) * 2007-02-16 2010-12-02 Arthur Louie Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
EP2257310A2 (en) * 2008-02-26 2010-12-08 Nerviano Medical Sciences S.r.l. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
DK2768484T3 (da) 2011-10-21 2019-10-07 Jazz Pharmaceuticals Res Llc Lyofiliserede liposomer
US9913822B2 (en) 2012-04-04 2018-03-13 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and therapeutic agent
KR102165348B1 (ko) 2012-05-09 2020-10-14 캔텍스 파마슈티칼즈, 인크. 골수억제의 치료
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
EP3291797B1 (en) 2015-05-04 2020-09-02 Versantis AG Method for preparing transmembrane ph-gradient vesicles
WO2017078009A1 (ja) * 2015-11-02 2017-05-11 富士フイルム株式会社 リポソーム組成物およびその製造方法
JP6976941B2 (ja) 2015-11-11 2021-12-08 セレーター ファーマシューティカルズ インコーポレイテッド 白血病に罹患している対象の治療レジメンを選択するためのアッセイ及び方法
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
JP2022502498A (ja) 2018-09-25 2022-01-11 セレーター ファーマシューティカルズ インコーポレイテッド 血液疾患の低強度治療
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
WO2022159497A1 (en) * 2021-01-20 2022-07-28 Board Of Regents, The University Of Texas System Combination therapy schedules to treat cancer
CN113181117B (zh) * 2021-03-22 2022-08-26 沈阳药科大学 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2025088367A1 (en) * 2023-10-27 2025-05-01 Jodas Expoim Pvt. Ltd Liposomal composition of idarubicin and cytarabine and process for preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (enExample) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
AU2002331481B2 (en) * 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
JP2006522026A (ja) 2003-04-02 2006-09-28 セレーター ファーマスーティカルズ、インク． カンプトセシンとフルオロピリミジンとを組み合わせた組成物
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents

Similar Documents

Publication Publication Date Title
JP2007533670A5 (enExample)
US12168021B2 (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
EP2632553B1 (en) A sustained release formulation of a non-steroidal anti-inflammatory drug
KR101301653B1 (ko) 항감염제의 지속적인 방출
ES2388064T3 (es) Formulaciones liposomales de agentes de antraciclina y análogos de citidina
CN1798544A (zh) 喜树碱和氟嘧啶的组合物
JP2004532186A5 (enExample)
HK40086177A (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
WO2006005415A3 (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases
HK1097194B (en) Liposomal formulations of anthracycline agents and cytidine analogs
HK1230985B (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
HK1230985A1 (en) Methods for treating pulmonary non-tuberculous mycobacterial infections